!
PROGRAMME(OF(LIVE(SESSIONS:((CET(timing(
(
The(programme(below(will(take(place(live.(This(time(schedule(corresponds(to(CEST(timing.(Click(here(to(adapt(the(
CET(time(schedule(to(your(own(time(zone.(
(
If(you(want(to(ask(questions(during(the(Panel(Discussions(and(Round(Tables(or(if(you(want(to(test(your(knowledge(
and( vote( during( Interactive( Case( presentations( and( debates,( please( make( sure( that( you( join( us( at( the( times(
indicated(below.(
(
Please(also(note(that(the(Meet(the(Expert(sessions(and(the(Mentored(Poster(Walk(will(take(place(100%(live.((
To(interact(you(must(be(online(at(the(times(indicated(in(the(programme(below.(
(
Thank(you(for(joining(us.(We(wish(you(a(good(meeting(
((((
!!
(
How(to(Diagnose(and(Treat(
LYMPHOMA(
November!6*8,!2020!
Chairpersons:!C.!Buske,!C.!Thieblemont,!A.!Younes!
(((((((( Friday,(November(6(
10:00*10:10( Welcome(
(
10:10*12:05! SESSION(I(–(Hodgkin’s(Disease(
! ( Chairs:(Andreas(Engert((Cologne)(and(Camille(Laurent((Toulouse)(
(
10:10*10:15! Introduction!
!
10:15*10:35! Diagnostics!!
! The!boundaries!of!Hodgkin!Lymphoma! Stefano!Pileri!(Milan)!
!
10:35*10:55! First!line!Treatment!
! Early!stages! Marc!André!(Namur,!Yvoir)!
!
10:55*11:15! First!line!Treatment!
! Intermediate/Advanced!stages! Andreas!Engert!(Cologne)!! !
!
11:15*11:35! Relapsed!Disease! Pier!Luigi!Zinzani!(Bologna)!
!
11:35*11:40! Refractory/relapsed/hodgkin/lymphoma:/the/profile/of// Maria/Eduarda/Couto/(Porto)/
/ patients/referred/to/autologous/stem/cell/transplantation/
!
11:40*12:05! Discussion/Q/&/A/!
!!
1
SCIENTIFIC PROGRAMME
SESSION I
HODGKIN’S DISEASE
DEBATE I
IS THERE STILL A ROLE
FOR COMBINED MODALITY
THERAPY FOR EARLY
STAGE CHL?
SESSION II
T-CELL LYMPHOMA
ROUNDTABLE I
FUTURE DIRECTIONS IN
T-CELL LYMPHOMA
SESSION III
FOLLICULAR LYMPHOMA
DEBATE II
CAN WE AVOID
CHEMOTHERAPY IN
THE MANAGEMENT OF
FOLLICULAR LYMPHOMA?
SESSION IV
RARE LYMPHOMAS –
MARGINAL ZONE
LYMPHOMA AND
WALDENSTRÖM M
ACROGLOBULINEMIA
ROUNDTABLE II – WHERE
TO GO IN RARE B-CELL
LYMPHOMAS
SESSION V
MANTLE CELL LYMPHOMA
SESSION VI
DIFFUSE LARGE B-CELL
LYMPHOMA
DEBATE III
DO WE STILL NEED ASCT
IN MCL?
SESSION VII
NOVEL THER APEUTIC
CONCEPTS IN B-CELL
LYMPHOMAS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
DISCLOSURES